At The Leukemia & Lymphoma Society (LLS), we have been fighting blood cancers by advancing breakthrough research for almost 70 years.
With a research agenda focused on finding cures, our work has helped millions impacted by cancer. Our research grants support the most innovative research because this foundational work has proven time and time again that this is the fastest way to cure blood cancer. And we partner with medical institutions, pharmaceutical and biotechnology companies, professional healthcare organizations and other key players across the cancer landscape to accelerate the development of new therapies.
Read about our latest investment here.
LLS commitment to new multi-year research grants in FY 2019.
Total current commitment
Total LLS research investment since our inception.
"Advances in technology have helped bring a deeper understanding of the drivers of cancer, and we are seeing remarkable progress in our quest for cures,” said Louis J. DeGennaro, Ph.D., LLS’s president and CEO. “Our longtime vision and investment in innovative research is having an impact on patients today. Remarkably, from the start of 2017 through today, the U.S. Food and Drug Administration has approved 32 blood cancer treatments and LLS helped advance 26 of these at some point in their development journey."
CDP: Career Development Program
Designed to support promising investigators in their developing careers.
SCOR: Specialized Center of Research
Funds multi-institutional, multi-disciplinary teams of researchers designed to synergistically engage in collaborative efforts to discover new approaches to treat patients with blood cancers.
TRP: Translational Research Program
Designed to bring promising preclinical research findings from the laboratory to clinical development.
TAP: Therapy Acceleration Program
Strategic initiative through which we partner directly with biotechnology companies to help accelerate the development of promising therapies.
Funding more research to understand the drivers of pediatric cancer and develop targeted therapies and immunotherapies.
Other Grant Programs
Screen to Lead grants support discovery specifically directed towards medicinal chemistry and/or drug target screening. And through special collaborations with foundations and researchers we can accelerate research, stimulate innovation and solve disease-specific challenges.
Hear from some of the world's most renowned blood cancer researchers about how LLS support helps makes it happen.
Louis J. DeGennaro, Ph.D, LLS’s president and CEO, and Steven T. Rosen, M.D., provost and chief scientific officer of City of Hope, and chairman of LLS’s Medical and Scientific Advisory Board, discuss LLS’s research funding programs.
LLS has invested more than $1 billion in research since our inception. Over that time, survival rates for many blood cancer patients have doubled, tripled and even quadrupled. Moreover, we have learned how to cure certain blood cancers. And many therapies first approved for blood cancers are now helping patients with other types of cancers and serious diseases.
But more than one third of blood cancer patients still do not survive five years after their diagnosis. So more funding is needed to advance more research and to ensure access to treatments to help save more lives.